Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
about
Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug ApprovalNorwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences.Special challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway.A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What are the Global Challenges?Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs.The impact of reference-pricing systems in Europe: a literature review and case studies.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Price comparison of high-cost originator medicines in European countries.Implications of external price referencing of pharmaceuticals in Middle East countries.A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial.Developing a model for agile supply: an empirical study from Iranian pharmaceutical supply chain.Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in EU pharmaceutical regulation.Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case.
P2860
Q28552883-70DBFD48-FAEF-448B-96DC-1B64348CEE74Q34467816-6A803AEB-C0DB-446A-9369-174176312477Q34494595-157695F7-95BE-4840-BAE5-E315FCEB9A5DQ35901619-335A591D-45EE-484D-8175-E6862B029802Q37847158-F1745EE1-B2E3-4E11-B631-3AAAD845E7D2Q37958057-9DC7A334-23F9-408A-A031-484305514DF4Q39072439-BDB839DF-4A88-4316-A679-9B67D74028C2Q39362176-A08CE068-C0A2-4E8A-AA3D-821E5A43F2ADQ40821943-0250F94F-33F4-4FD5-BF7E-5B315EC1D8E2Q42374169-2E69BAB3-B0B9-4DCF-86D9-C9F9AD023A3AQ42927316-48C56C1D-B54C-47BF-8372-CB769B1FD0B5Q53809508-A91CD422-0D12-4F5F-BA7D-61301C392771Q55220041-F48DFCCB-5158-4CED-A528-AE795CC95B60
P2860
Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Price control as a strategy fo ...... orway in the period 1994-2004?
@en
Price control as a strategy fo ...... orway in the period 1994-2004?
@nl
type
label
Price control as a strategy fo ...... orway in the period 1994-2004?
@en
Price control as a strategy fo ...... orway in the period 1994-2004?
@nl
prefLabel
Price control as a strategy fo ...... orway in the period 1994-2004?
@en
Price control as a strategy fo ...... orway in the period 1994-2004?
@nl
P2093
P1433
P1476
Price control as a strategy fo ...... orway in the period 1994-2004?
@en
P2093
Anne Marie Horn
Else-Lydia Toverud
Helle Håkonsen
P304
P356
10.1016/J.HEALTHPOL.2008.09.018
P577
2008-11-29T00:00:00Z